PD‐1/PD‐L1 immune checkpoint inhibitors (ICIs) disrupt the PD‐1/PD‐L1 interaction, counteracting the suppressive effects of tumor cells on T cells [1]. This evidence concerns the gene PDCD1 and neoplasm.